

# British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA Study)




Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.

Over 30,000 patients registered in the study since 2001.

**NOW ACCEPTING NEW REGISTRATIONS AND FOLLOW-UP DATA ONLINE VIA THE NEW WEB PORTAL!**

To sign up please visit <https://bsrbr.org/database/>

## Eligibility for registration

	Diagnosis of Rheumatoid Arthritis		Aged 16 Years or over	Starting eligible biologic treatment	
---	-----------------------------------	---	-----------------------	--------------------------------------	---

### ANTI-TNF

- HUMIRA**  
(adalimumab originator)\*
- ENBREL**  
(etanercept originator)\*
- REMICADE**  
(infliximab originator)\*

\*patients must be biologic, biosimilar & targeted therapy naive to be eligible


### BIOSIMILARS

<ul style="list-style-type: none"> <li><b>HULIO</b> (adalimumab)</li> <li><b>AMGEVITA</b> (adalimumab)</li> <li><b>HYRIMOZ</b> (adalimumab)</li> <li><b>IMRALDI</b> (adalimumab)</li> <li><b>RIXATHON</b> (rituximab)</li> <li><b>IDACIO</b> (adalimumab)</li> <li><b>RUXIENCE</b> (rituximab)</li> </ul>	<ul style="list-style-type: none"> <li><b>ERELZI</b> (etanercept)</li> <li><b>BENEPALI</b> (etanercept)</li> <li><b>INFLECTRA</b> (infliximab)</li> <li><b>REMSIMA IV</b> (infliximab)</li> <li><b>REMSIMA SC</b> (infliximab)</li> <li><b>FLIXABI</b> (infliximab)</li> </ul>
---	--

### OTHER TARGETED THERAPIES

<ul style="list-style-type: none"> <li><b>OLUMIANT</b> (baracitinib)</li> <li><b>CIMZIA</b> (certolizumab)</li> <li><b>XELJANZ</b> (tofacitinib)</li> <li><b>JYSELECA</b> (filgotinib)</li> </ul>	<ul style="list-style-type: none"> <li><b>ROACTEMRA</b> (tocilizumab)</li> <li><b>KEVZARA</b> (sarilumab)</li> <li><b>RINVOQ</b> (upadacitinib)</li> </ul>
---	--

Registration within 6 months of the therapy start date\*



\*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Please contact the BSRBR-RA team with any questions

0161 275 1652 / 7390 [biologics.register@manchester.ac.uk](mailto:biologics.register@manchester.ac.uk)